The impact of urine biomarkers for prostate cancer detection-A systematic state of the art review.

Stefan Plas¹, Felix Melchior¹, Gerhard P Aigner¹, Maria Frantzi², Jan Pencik³, Mona Kafka¹, Isabel Heidegger⁴

¹Medical University of Innsbruck, Department of Urology, Innsbruck, Austria.

²Department of Biomarker Research, Mosaiques diagnostics GmbH, Hannover, Germany.

³Iambic Therapeutics, 5627 Oberlin Drive, San Diego, CA 92121, USA.

⁴Medical University of Innsbruck, Department of Urology, Innsbruck, Austria. Electronic address: Isabel-maria.heidegger@i-med.ac.at.

PubMed DOI

Abstract

BACKGROUND: Prostate cancer (PCa) screening primarily relies on Prostate-Specific Antigen (PSA), which has low specificity and therefore leads to unnecessary biopsies. Consequently, there is a growing need for, ideally, non-invasive biomarkers. Liquid biopsy, a diagnostic approach analyzing circulating tumor components in body fluids, has emerged as a promising diagnostic tool for various cancers,…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.